US 12,344,570 B2
Aminotetraline activators of serotonin receptors
Glenn Short, Scituate, MA (US); Robert B. Perni, Marlborough, MA (US); and Tanweer A. Khan, Bridgewater, NJ (US)
Assigned to Atai Therapeutics, Inc., New York, NY (US)
Filed by Atai Therapeutics, Inc., New York, NY (US)
Filed on Aug. 23, 2023, as Appl. No. 18/454,711.
Application 18/454,711 is a continuation of application No. 18/146,785, filed on Dec. 27, 2022, granted, now 11,827,580.
Claims priority of provisional application 63/294,030, filed on Dec. 27, 2021.
Prior Publication US 2024/0300885 A1, Sep. 12, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07C 211/42 (2006.01); C07D 217/08 (2006.01)
CPC C07C 211/42 (2013.01) [C07D 217/08 (2013.01)] 18 Claims
 
1. A compound of Formula (III):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof; wherein,
R1 is methyl;
R2 and R3 are independently H, C1-C6 alkyl, halogen, CN, or OR7;
R4 and R5 are H;
R7 is H, C1-C6 alkyl, or C1-C6 fluoroalkyl; and
X is CH or N;
wherein the compound is not 5,8-dimethoxy-6-methyl-1,2,3,4-tetrahydronaphthalen-2-amine; 5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine; 6-bromo-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine; 7-bromo-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine; 5,7,8-trimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine;
or 5,6,8-trimethoxy-1,2,3,4-tetrahydronaphthalen-2-amine.